Bills · HR 7837
IN COMMITTEE· 119TH CONGRESS
House BillHR 7837Health
Most Favored Patient Act of 2026
INTRO MAR 5· LAST ACTION MAR 5
READING
6MIN
COSPONSORS
0
READER REACTIONS0 TOTAL
NO VOTES YET · BE THE FIRST
- Introduced only
LEGISLATIVE PROGRESS
STEP 2 / 8Introduced
In Committee
Reported
Passed House
Passed Senate
Conference
To President
Became Law
WHAT THE BILL DOES
AI-writtenVoters should care about this bill because it directly addresses the persistent issue of high prescription drug costs in the United States, which is a major concern for many families and seniors. If this bill becomes law, it could significantly reduce the amount that Medicare and Medicaid pay for certain drugs, potentially leading to lower premiums, co-pays, and deductibles for beneficiaries. It also ties into broader efforts to make healthcare more affordable.
Furthermore, the bill includes an incentive for pharmaceutical companies to increase drug manufacturing within the United States. This could create jobs, bolster domestic supply chains, and reduce reliance on foreign production, which has become a focus due to recent global events. Without this bill, drug prices for Medicare and Medicaid beneficiaries would continue to be set primarily by current market dynamics, which often results in higher costs compared to other developed nations, and there would be no direct federal incentive for increased domestic drug manufacturing tied to pricing.
KEY PROVISIONS
4AI-extractedPROVISION 01
Requires the Center for Medicare and Medicaid Innovation (CMMI) to implement a 'Most Favored Nations Pricing Model' for drugs.
This mandates a significant change in how prescription drug prices are determined for federal health programs, potentially leading to lower costs.
PROVISION 02
Defines the 'Most Favored Nations price' as the second-lowest price for a drug in a group of eight specific developed countries.
This establishes the benchmark for how much certain drugs can cost in the U.S. for Medicare and Medicaid beneficiaries, directly linking prices to international markets.
PROVISION 03
Applies these new drug pricing rules to individuals enrolled in Medicare (Parts B, C, D) and Medicaid.
Ensures that a broad segment of the U.S. population relying on federal health programs could benefit from reduced drug costs.
PROVISION 04
Allows drug manufacturers to avoid the mandatory pricing model if they enter into an agreement to provide the lower international price AND commit to increasing U.S. manufacturing operations.
This provides an incentive for pharmaceutical companies to invest in domestic drug production while still aiming for lower drug prices.
SPONSORSHIP
1 + 0
R· Pennsylvania
YRS IN OFFICE
7
BILLS LED
20
ACTION TIMELINE
2 EVENTSMAR 5
Introduced in House
MAR 5
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
BILL INFO
TypeHouse Bill
NumberHR 7837
Congress119th
StatusIn Committee
IntroducedMar 5, 2026
Last actionMar 5, 2026
READER REACTIONS
OVERALL SENTIMENT
No reactions yet. Be the first to weigh in.
Discussion
Loading comments...
IN COMMITTEE· 119TH CONGRESS · WAYS AND MEANS COMMITTEE · INTRODUCED MAR 5, 2026
House BillHR 7837Health
Most Favored Patient Act of 2026
INTRODUCED MAR 5, 2026· LAST ACTION MAR 5, 2026
PASSAGE CHANCES
—%
READING
6 min
COSPONSORS
0
COMPLEXITY
Moderate
